Terns Pharmaceuticals Inc is a biotechnology business based in the US. Terns Pharmaceuticals shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Terns Pharmaceuticals employs 41 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.40 |
|---|---|
| 52-week range | $1.45 - $13.77 |
| 50-day moving average | $1.85 |
| 200-day moving average | $5.42 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.01 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.4 from 2022-06-29
| 1 week (2022-06-23) | 5.73% |
|---|---|
| 1 month (2022-05-27) | 45.45% |
| 3 months (2022-03-30) | -17.24% |
| 6 months (2021-12-30) | -61.35% |
| 1 year (2021-06-30) | -80.42% |
|---|---|
| 2 years (2020-06-26) | N/A |
| 3 years (2019-06-26) | N/A |
| 5 years (2017-06-26) | N/A |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -17.7% |
| Return on equity TTM | -29.87% |
| Profit margin | 0% |
| Book value | $5.89 |
| Market capitalisation | $57.4 million |
TTM: trailing 12 months
We're not expecting Terns Pharmaceuticals to pay a dividend over the next 12 months.
Terns Pharmaceuticals's shares were split on a 1000:50 basis on 3 November 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals shares which in turn could have impacted Terns Pharmaceuticals's share price.
Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.